Vistagen Therapeutics (VTGN) Non-Current Assets (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Non-Current Assets of $1.6 million for Q1 2026, down 10.49% sequentially from $1.8 million in Q4 2025, and down 28.43% YoY from $2.3 million in Q1 2025.
Vistagen Therapeutics (VTGN) Non-Current Assets (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Non-Current Assets for 14 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 28.43% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 22.79% YoY) and the FY2026 annual result came in at $1.6 million, down 28.43% from the prior year.
- Non-Current Assets retreated to $1.6 million in Q1 2026 per VTGN's latest filing, from $1.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $3.8 million in Q3 2022 and troughed at $1.6 million in Q1 2026.
- A 5-year average of $2.8 million and a median of $3.0 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets retreated 1.74% in 2023, then retreated 28.43% in 2026.
- Over 5 years, Non-Current Assets stood at $3.7 million in 2022, then dropped by 19.1% to $3.0 million in 2023, then decreased by 19.91% to $2.4 million in 2024, then decreased by 23.46% to $1.8 million in 2025, then dropped by 10.49% to $1.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.6 million, $1.8 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 18.06 Bn |
| 10 | Vistagen Therapeutics | 10.39 Mn | 10.39 Mn | - | 1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.62 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 2.98 Mn |
| Dec 31, 2023 | 2.95 Mn |
| Sep 30, 2023 | 3.12 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 3.58 Mn |
| Dec 31, 2022 | 3.65 Mn |
| Sep 30, 2022 | 3.79 Mn |
| Jun 30, 2022 | 3.73 Mn |
| Mar 31, 2022 | 3.65 Mn |
| Dec 31, 2021 | 3.77 Mn |
| Sep 30, 2021 | 4.06 Mn |
| Jun 30, 2021 | 4.08 Mn |